Noa Krawczyk, PhD
NYU Langone Health, Division of Epidemiology, Center for Opioid Epidemiology and Policy, Department of Population Health - Assistant Professor
Email: noa.krawczyk@nyulangone.org
Education
PhD, Mental Health, Johns Hopkins Bloomberg School of Public HealthBA, Biology, Hunter College at the City University of New York – Macaulay Honors College
Research Interests
Substance use, Opioids, Overdose, Health services, Mental health, Criminal justice, Treatment BIO
Noa Krawczyk is an Assistant Professor in the Department of Population Health at NYU School of Medicine and a member of the Center for Opioid Epidemiology and Policy. She completed her PhD in the Department of Mental Health at the Johns Hopkins Bloomberg School of Public Health, where she studied substance use epidemiology, and previously worked as a Fulbright research scholar to study treatment and health services among cocaine users in Brazil. Her research focuses on studying ways to address barriers to evidence-based treatment for opioid use disorders and improving quality and effectiveness of care, especially among vulnerable groups such as persons with criminal justice involvement. Her work centers on bridging research and practice by collaborating with health organizations, public health and government agencies and advancing science that can help inform evidence-based policies and practices that reduce harm and promote long term recovery. Projects
Principal Investigator, Beyond Treatment Initiation: Enhancing Opioid Use Disorder Care Transitions Across Health System Touchpoints. Active
Principal Investigator, Characterizing Complex OUD Care Trajectories and Outcomes Following Acute Service Utilization: A Population-Based Data Linkage Study. Active
Principal Investigator, NY MOVES: Evaluating the Impact of New York’s Methadone Outreach VEhicleS. Active
Principal Investigator, Simulating the Impact of Office-Based Methadone Prescribing and Pharmacy Dispensing on OUD Treatment and Overdose in New York State: An Agent-Based Modeling Approach. Active
Principal Investigator, Trends in Psychosis Related to Hospitalizations Among Youth Following Cannabis Legalization in Colorado. Completed
Publications
Recent
Krawczyk N, Scott J, Miller M, Coulter A, Ferguson A, Frank D, Jordan A, Joudrey P, Kimmel SD, Levander XA, Potee R, Roberts KE, Russell D, Simon R, Sue KL, Suen LW, Vincent L, Voyles N, Simon C (2025).
Envisioning a humane and accessible US methadone treatment system: Generating policy and practice recommendations from the Liberate Methadone movement
Substance Use & Addiction Journal [Epub 2026 Oct 26]. doi: 10.1177/29767342251377189.
Envisioning a humane and accessible US methadone treatment system: Generating policy and practice recommendations from the Liberate Methadone movement
Substance Use & Addiction Journal [Epub 2026 Oct 26]. doi: 10.1177/29767342251377189.
Krawczyk N, Miller M, Bórquez I, Rutherford C, Bobashev G, Mund P, Keyes K, Cerda M, Jordan AE (2025).
Simulating the impact of methadone prescribing and pharmacy dispensing on opioid treatment and overdose in New York State: A study protocol for an agent-based modeling study
PLoS One, 20 (10), e0335123. doi: 10.1371/journal.pone.0335123. PMCID: PMC12543120.
Simulating the impact of methadone prescribing and pharmacy dispensing on opioid treatment and overdose in New York State: A study protocol for an agent-based modeling study
PLoS One, 20 (10), e0335123. doi: 10.1371/journal.pone.0335123. PMCID: PMC12543120.
Matson TE, Navarro MA, Idu A, Bobb JF, Patrick BM, Phillips R, Barrett TD, Rossi FS, Krawczyk N, Doud R, Rogers K, Davis CJ, Caldeiro R, Glass JE (2025).
Design of a cluster-randomized, hybrid type 1 effectiveness-implementation trial of a care navigation intervention to increase substance use disorder treatment engagement: Study protocol
Addiction Science and Clinical Practice, 20 (1), 78. doi: 10.1186/s13722-025-00605-7. PMCID: PMC12486859.
Design of a cluster-randomized, hybrid type 1 effectiveness-implementation trial of a care navigation intervention to increase substance use disorder treatment engagement: Study protocol
Addiction Science and Clinical Practice, 20 (1), 78. doi: 10.1186/s13722-025-00605-7. PMCID: PMC12486859.
Shah H, Whaley S, Desai IK, Song M, Meyer A, Heidari O, Allen ST, Krawczyk N, Sherman SG, Saloner B, Harris SJ (2025).
A qualitative study on the impact of COVID-19 on overdose risk from the perspective of survivors and witnesses of drug overdose: Lessons for future public health emergencies
Substance Use and Misuse [Epub 2025 Sep 30]. doi: 10.1080/10826084.2025.2562455.
A qualitative study on the impact of COVID-19 on overdose risk from the perspective of survivors and witnesses of drug overdose: Lessons for future public health emergencies
Substance Use and Misuse [Epub 2025 Sep 30]. doi: 10.1080/10826084.2025.2562455.
Choi S, Hong S, Fawole A, Heck A, Lincourt P, Jordan AE, Hussain S, O'Grady MA, Bao Y, Cleland CM, Adhikari S, Cerda M, Krawczyk N, Kyanko K, McNeely J, Cunningham C, Mijanovich T, Howland R, Thornburg O, Hutchinson M, Liebmann E, Neighbors CJ (2025).
Advancing person-centered care: Protocol for quality measurement and management (QM2) in the New York State system for opioid use disorder treatment
PLoS One, 20 (9), e0330882. doi: 10.1371/journal.pone.0330882. PMCID: PMC12478935.
Advancing person-centered care: Protocol for quality measurement and management (QM2) in the New York State system for opioid use disorder treatment
PLoS One, 20 (9), e0330882. doi: 10.1371/journal.pone.0330882. PMCID: PMC12478935.
Notable
Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap
Journal of Substance Abuse Treatment, 103, 1-8. doi: 10.1016/j.jsat.2019.05.002. PMCID: PMC6612429.
Krawczyk N, Picher CE, Feder KA, Saloner B (2017).
Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine
Health Affairs, 36 (12), 2046-2053. doi: 10.1377/hlthaff.2017.0890. PMCID: PMC6035729.
Dr. Krawczyk's MyBibliography Profile
Selected Press